Ginkgo biloba is one of the best-characterized botanicals in the cognitive-supplement space — it has a dedicated regulatory monograph in several countries, and a large trial base compared with newer adaptogens. That maturity is exactly what makes its side-effect and evidence picture unusually clear: it is generally well tolerated, but the enhancement claims made for healthy adults outrun what the largest trials actually found.

The short version

In studies of standardized leaf extract (commonly EGb 761) at 120–240 mg per day, ginkgo has generally been reported as mild in its side-effect profile. The most-discussed caution is not a common mild symptom, but a less frequent, more serious one: bleeding risk when combined with anticoagulant or antiplatelet medication.

Side effects reported in trials

  • Headache — one of the more commonly reported mild complaints.
  • Gastrointestinal upset — mild stomach discomfort in some users.
  • Dizziness — reported occasionally, generally mild.
  • Bleeding events — uncommon overall, but the specific safety signal that carries the most clinical weight (see below).

The bleeding-risk interaction, specifically

Ginkgo has documented effects on platelet function, which is the mechanism behind its most important caution: it may add to the bleeding risk of anticoagulants and antiplatelet drugs such as warfarin, aspirin, and clopidogrel. This is the reason standard guidance recommends stopping ginkgo one to two weeks before scheduled surgery, and why anyone on blood-thinning medication should discuss ginkgo with a clinician rather than assume it is a neutral, low-risk addition.

Who should avoid or check first

  • One to two weeks before any scheduled surgery, given the bleeding-risk mechanism above.
  • Anyone taking anticoagulant or antiplatelet medication — discuss with a clinician before combining.
  • Pregnant or breastfeeding — not established as safe in this population.
  • Seizure disorders — ginkgo seed (not the standardized leaf extract used in supplements) contains a compound linked to seizure risk, and unstandardized or contaminated leaf extracts have occasionally raised the same concern; standardized extract with a stated ginkgolic-acid limit is the safer choice.

Where the enhancement evidence honestly stands

This is the part that most often gets overstated. Laws et al. (2012), a meta-analysis, found no cognitive-enhancement benefit from ginkgo in healthy people. Two large, long-term prevention trials reinforce this from a different angle: the GEM trials (DeKosky 2008; Snitz 2009) found that ginkgo did not prevent dementia or slow cognitive decline in older adults, and GuidAge (Vellas 2012) found long-term ginkgo did not reduce progression to Alzheimer's dementia. Ginkgo's evidence is more consistent in people with existing mild cognitive impairment or dementia symptoms, at 240 mg/day — a genuinely different population and claim than "boosts memory in a healthy adult."

How to think about it

Ginkgo's tolerability profile is reassuring for most people at studied doses, and its one serious caution — bleeding risk with blood-thinning medication or before surgery — is well-characterized and easy to plan around if you know to ask. Its enhancement case for a healthy, unimpaired adult, though, is the weakest part of the ginkgo story, and worth knowing before paying a premium for a "memory boost" claim.

References

  • Laws KR, Sweetnam H, Kondel TK. "Is Ginkgo biloba a cognitive enhancer in healthy individuals? A meta-analysis." Human Psychopharmacology, 2012;27(6):527–533. PMID: 23001963.
  • DeKosky ST, Williamson JD, Fitzpatrick AL, et al. "Ginkgo biloba for prevention of dementia: a randomized controlled trial." JAMA, 2008;300(19):2253–2262. PMID: 19017911.
  • Snitz BE, O'Meara ES, Carlson MC, et al. "Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial." JAMA, 2009;302(24):2663–2670. PMID: 20040554.
  • Vellas B, Coley N, Ousset PJ, et al. "Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial." Lancet Neurology, 2012;11(10):851–859. PMID: 22959217.